|United States Of America||Issued Patent||10,337,051||07/02/2019||2016-163|
|United Kingdom||Issued Patent||2557153||03/20/2019||2016-163|
|European Patent Office||Published Application||3471749||04/24/2019||2016-163|
|Germany||Published Application||21 2017 000 061||01/10/2019||2016-163|
|Germany||Published Application||21 2017 000 062||01/10/2019||2016-163|
|United States Of America||Published Application||20180208976||07/26/2018||2016-163|
|United States Of America||Published Application||20180208977||07/26/2018||2016-163|
|Australia||Published Application||WO 2017/218573||12/21/2017||2016-163|
|Canada||Published Application||WO 2017/218573||12/21/2017||2016-163|
|Japan||Published Application||WO 2017/218573||12/21/2017||2016-163|
|Patent Cooperation Treaty||Published Application||WO2017218573||12/21/2017||2016-163|
Additional Patent Pending
Bacterial adaptive immune systems employ CRISPRs and CRISPR-associated (Cas) proteins for RNA-guided nucleic acid cleavage. Although generally targeted to DNA substrates, the Type VI CRISPR system directs interference complexes against single-stranded RNA substrates and in Type VI CRISPR systems, the single-subunit Cas13a/C2c2 protein functions as an RNA-guided RNA endonuclease.
UC Berkeley researchers have discovered that the CRISPR-Cas13a/C2c2 has two distinct RNase activities that enable both single stranded target RNA detection and multiplexed guide-RNA processing. These dual RNase functions were found to be chemically and mechanistically different from each other and from the CRISPR RNA processing behavior of the evolutionarily unrelated CRISPR enzyme Cpf1. Methods for detecting the single stranded target RNA were also discovered using a Cas13a/C2c2 guide RNA and a Cas13a/C2c2 protein in a sample have a plurality of RNAs as well as methods of cleaving a precursor Cas13a/C2c2 guide RNA into two or more Cas13a/C2c2 guide RNAs.